APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody-drug Conjugates for Tumors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antibody-drug Conjugates for Tumors Market Analysis and Forecast 2026-2032

26 December 2025191 pages

Choose your research edition.

Industry ResearchAntibody-drug Conjugates for Tumors Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody-drug Conjugates for Tumors Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antibody-drug Conjugates for Tumors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody-drug Conjugates for Tumors Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody-drug Conjugates for Tumors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Antibody-drug Conjugates for Tumors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antibody-drug Conjugates for Tumors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antibody-drug Conjugates for Tumors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antibody-drug Conjugates for Tumors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antibody-drug Conjugates for Tumors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antibody-drug Conjugates for Tumors include Takeda, RemeGen, Roche（Genentech）, Rakuten Medical, Gilead Sciences, Pfizer（Seagen), GSK, Daiichi Sankyo and AbbVie(ImmunoGen), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antibody-drug Conjugates for Tumors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antibody-drug Conjugates for Tumors, also provides the sales of main regions and countries. Of the upcoming market potential for Antibody-drug Conjugates for Tumors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody-drug Conjugates for Tumors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antibody-drug Conjugates for Tumors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antibody-drug Conjugates for Tumors sales, projected growth trends, production technology, application and end-user industry.

Antibody-drug Conjugates for Tumors Segment by Company

Takeda

RemeGen

Roche（Genentech）

Rakuten Medical

Gilead Sciences

Pfizer（Seagen)

GSK

Daiichi Sankyo

AbbVie(ImmunoGen)

AstraZeneca

ADC Therapeutics

Antibody-drug Conjugates for Tumors Segment by Type

DNA Damaging Drugs

Tubulin Inhibitors

Other

Antibody-drug Conjugates for Tumors Segment by Application

Hematological Tumors

Solid Tumors

Antibody-drug Conjugates for Tumors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody-drug Conjugates for Tumors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody-drug Conjugates for Tumors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody-drug Conjugates for Tumors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antibody-drug Conjugates for Tumors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antibody-drug Conjugates for Tumors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody-drug Conjugates for Tumors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibody-drug Conjugates for Tumors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DNA Damaging Drugs Major Manufacturers Table 3. Tubulin Inhibitors Major Manufacturers Table 4. Other Major Manufacturers Table 5. Global Antibody-drug Conjugates for Tumors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hematological Tumors Major Manufacturers Table 7. Solid Tumors Major Manufacturers Table 8. Antibody-drug Conjugates for Tumors Industry Trends Table 9. Antibody-drug Conjugates for Tumors Industry Drivers Table 10. Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges Table 11. Antibody-drug Conjugates for Tumors Industry Restraints Table 12. Global Antibody-drug Conjugates for Tumors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Antibody-drug Conjugates for Tumors Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Antibody-drug Conjugates for Tumors Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2026) Table 16. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2027-2032) Table 17. Global Antibody-drug Conjugates for Tumors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2026) & (K Units) Table 19. Global Antibody-drug Conjugates for Tumors Sales by Region (2027-2032) & (K Units) Table 20. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021-2026) Table 21. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2027-2032) Table 22. Global Antibody-drug Conjugates for Tumors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Antibody-drug Conjugates for Tumors Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers (2021-2026) Table 26. Global Antibody-drug Conjugates for Tumors Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Antibody-drug Conjugates for Tumors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Antibody-drug Conjugates for Tumors Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Antibody-drug Conjugates for Tumors Manufacturers, Product Type & Application Table 30. Global Antibody-drug Conjugates for Tumors Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Antibody-drug Conjugates for Tumors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Antibody-drug Conjugates for Tumors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2026) Table 37. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2027-2032) Table 38. Global Antibody-drug Conjugates for Tumors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 40. Global Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 41. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2026) Table 42. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2027-2032) Table 43. Global Antibody-drug Conjugates for Tumors Price by Type (2021-2026) & (US$/Unit) Table 44. Global Antibody-drug Conjugates for Tumors Price by Type (2027-2032) & (US$/Unit) Table 45. Global Antibody-drug Conjugates for Tumors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2026) Table 49. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2027-2032) Table 50. Global Antibody-drug Conjugates for Tumors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 52. Global Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 53. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2026) Table 54. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2027-2032) Table 55. Global Antibody-drug Conjugates for Tumors Price by Application (2021-2026) & (US$/Unit) Table 56. Global Antibody-drug Conjugates for Tumors Price by Application (2027-2032) & (US$/Unit) Table 57. Takeda Company Information Table 58. Takeda Business Overview Table 59. Takeda Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Takeda Antibody-drug Conjugates for Tumors Product Portfolio Table 61. Takeda Recent Development Table 62. RemeGen Company Information Table 63. RemeGen Business Overview Table 64. RemeGen Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. RemeGen Antibody-drug Conjugates for Tumors Product Portfolio Table 66. RemeGen Recent Development Table 67. Roche（Genentech） Company Information Table 68. Roche（Genentech） Business Overview Table 69. Roche（Genentech） Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio Table 71. Roche（Genentech） Recent Development Table 72. Rakuten Medical Company Information Table 73. Rakuten Medical Business Overview Table 74. Rakuten Medical Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio Table 76. Rakuten Medical Recent Development Table 77. Gilead Sciences Company Information Table 78. Gilead Sciences Business Overview Table 79. Gilead Sciences Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio Table 81. Gilead Sciences Recent Development Table 82. Pfizer（Seagen) Company Information Table 83. Pfizer（Seagen) Business Overview Table 84. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio Table 86. Pfizer（Seagen) Recent Development Table 87. GSK Company Information Table 88. GSK Business Overview Table 89. GSK Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. GSK Antibody-drug Conjugates for Tumors Product Portfolio Table 91. GSK Recent Development Table 92. Daiichi Sankyo Company Information Table 93. Daiichi Sankyo Business Overview Table 94. Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio Table 96. Daiichi Sankyo Recent Development Table 97. AbbVie(ImmunoGen) Company Information Table 98. AbbVie(ImmunoGen) Business Overview Table 99. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio Table 101. AbbVie(ImmunoGen) Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio Table 106. AstraZeneca Recent Development Table 107. ADC Therapeutics Company Information Table 108. ADC Therapeutics Business Overview Table 109. ADC Therapeutics Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio Table 111. ADC Therapeutics Recent Development Table 112. North America Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (US$ Million) Table 113. North America Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (US$ Million) Table 114. North America Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 115. North America Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 116. North America Antibody-drug Conjugates for Tumors Sales Price by Type (2021-2026) & (US$/Unit) Table 117. North America Antibody-drug Conjugates for Tumors Sales Price by Type (2027-2032) & (US$/Unit) Table 118. North America Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 121. North America Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 122. North America Antibody-drug Conjugates for Tumors Sales Price by Application (2021-2026) & (US$/Unit) Table 123. North America Antibody-drug Conjugates for Tumors Sales Price by Application (2027-2032) & (US$/Unit) Table 124. North America Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. North America Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 126. North America Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 127. North America Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 128. North America Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 129. North America Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 130. North America Antibody-drug Conjugates for Tumors Sales Price by Country (2021-2026) & (US$/Unit) Table 131. North America Antibody-drug Conjugates for Tumors Sales Price by Country (2027-2032) & (US$/Unit) Table 132. United States Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 133. Canada Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 134. Mexico Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 135. Europe Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (US$ Million) Table 136. Europe Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (US$ Million) Table 137. Europe Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 138. Europe Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 139. Europe Antibody-drug Conjugates for Tumors Sales Price by Type (2021-2026) & (US$/Unit) Table 140. Europe Antibody-drug Conjugates for Tumors Sales Price by Type (2027-2032) & (US$/Unit) Table 141. Europe Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (US$ Million) Table 142. Europe Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (US$ Million) Table 143. Europe Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 144. Europe Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 145. Europe Antibody-drug Conjugates for Tumors Sales Price by Application (2021-2026) & (US$/Unit) Table 146. Europe Antibody-drug Conjugates for Tumors Sales Price by Application (2027-2032) & (US$/Unit) Table 147. Europe Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 149. Europe Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 150. Europe Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 151. Europe Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 152. Europe Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 153. Europe Antibody-drug Conjugates for Tumors Sales Price by Country (2021-2026) & (US$/Unit) Table 154. Europe Antibody-drug Conjugates for Tumors Sales Price by Country (2027-2032) & (US$/Unit) Table 155. Germany Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 156. France Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 157. U.K. Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 158. Italy Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 159. Russia Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 160. Spain Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 161. Netherlands Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 162. Switzerland Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 163. Sweden Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 164. Poland Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 165. China Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (US$ Million) Table 166. China Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (US$ Million) Table 167. China Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 168. China Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 169. China Antibody-drug Conjugates for Tumors Sales Price by Type (2021-2026) & (US$/Unit) Table 170. China Antibody-drug Conjugates for Tumors Sales Price by Type (2027-2032) & (US$/Unit) Table 171. China Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (US$ Million) Table 172. China Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (US$ Million) Table 173. China Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 174. China Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 175. China Antibody-drug Conjugates for Tumors Sales Price by Application (2021-2026) & (US$/Unit) Table 176. China Antibody-drug Conjugates for Tumors Sales Price by Application (2027-2032) & (US$/Unit) Table 177. Asia Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (US$ Million) Table 178. Asia Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (US$ Million) Table 179. Asia Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 180. Asia Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 181. Asia Antibody-drug Conjugates for Tumors Sales Price by Type (2021-2026) & (US$/Unit) Table 182. Asia Antibody-drug Conjugates for Tumors Sales Price by Type (2027-2032) & (US$/Unit) Table 183. Asia Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (US$ Million) Table 184. Asia Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (US$ Million) Table 185. Asia Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 186. Asia Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 187. Asia Antibody-drug Conjugates for Tumors Sales Price by Application (2021-2026) & (US$/Unit) Table 188. Asia Antibody-drug Conjugates for Tumors Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Asia Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. Asia Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 191. Asia Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 192. Asia Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 193. Asia Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 194. Asia Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 195. Asia Antibody-drug Conjugates for Tumors Sales Price by Country (2021-2026) & (US$/Unit) Table 196. Asia Antibody-drug Conjugates for Tumors Sales Price by Country (2027-2032) & (US$/Unit) Table 197. Japan Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 198. South Korea Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 199. India Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 200. Australia Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 201. Taiwan Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 202. Southeast Asia Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 203. SAMEA Antibody-drug Conjugates for Tumors Revenue by Type (2021-2026) & (US$ Million) Table 204. SAMEA Antibody-drug Conjugates for Tumors Revenue by Type (2027-2032) & (US$ Million) Table 205. SAMEA Antibody-drug Conjugates for Tumors Sales by Type (2021-2026) & (K Units) Table 206. SAMEA Antibody-drug Conjugates for Tumors Sales by Type (2027-2032) & (K Units) Table 207. SAMEA Antibody-drug Conjugates for Tumors Sales Price by Type (2021-2026) & (US$/Unit) Table 208. SAMEA Antibody-drug Conjugates for Tumors Sales Price by Type (2027-2032) & (US$/Unit) Table 209. SAMEA Antibody-drug Conjugates for Tumors Revenue by Application (2021-2026) & (US$ Million) Table 210. SAMEA Antibody-drug Conjugates for Tumors Revenue by Application (2027-2032) & (US$ Million) Table 211. SAMEA Antibody-drug Conjugates for Tumors Sales by Application (2021-2026) & (K Units) Table 212. SAMEA Antibody-drug Conjugates for Tumors Sales by Application (2027-2032) & (K Units) Table 213. SAMEA Antibody-drug Conjugates for Tumors Sales Price by Application (2021-2026) & (US$/Unit) Table 214. SAMEA Antibody-drug Conjugates for Tumors Sales Price by Application (2027-2032) & (US$/Unit) Table 215. SAMEA Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 216. SAMEA Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 217. SAMEA Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 218. SAMEA Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 219. SAMEA Antibody-drug Conjugates for Tumors Sales by Country (2021-2026) & (K Units) Table 220. SAMEA Antibody-drug Conjugates for Tumors Sales by Country (2027-2032) & (K Units) Table 221. SAMEA Antibody-drug Conjugates for Tumors Sales Price by Country (2021-2026) & (US$/Unit) Table 222. SAMEA Antibody-drug Conjugates for Tumors Sales Price by Country (2027-2032) & (US$/Unit) Table 223. Brazil Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 224. Argentina Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 225. Chile Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 226. Colombia Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 227. Peru Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 228. Saudi Arabia Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 229. Israel Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 230. UAE Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 231. Turkey Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 232. Iran Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 233. Egypt Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Table 234. Key Raw Materials Table 235. Raw Materials Key Suppliers Table 236. Antibody-drug Conjugates for Tumors Distributors List Table 237. Antibody-drug Conjugates for Tumors Customers List Table 238. Research Programs/Design for This Report Table 239. Authors List of This Report Table 240. Secondary Sources Table 241. Primary Sources List of Figures Figure 1. Antibody-drug Conjugates for Tumors Image Figure 2. Global Antibody-drug Conjugates for Tumors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody-drug Conjugates for Tumors Market Size Share 2021 VS 2025 VS 2032 Figure 4. DNA Damaging Drugs Image Figure 5. Tubulin Inhibitors Image Figure 6. Other Image Figure 7. Global Antibody-drug Conjugates for Tumors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antibody-drug Conjugates for Tumors Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hematological Tumors Image Figure 10. Solid Tumors Image Figure 11. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Antibody-drug Conjugates for Tumors Revenue (2021-2032) & (US$ Million) Figure 13. Global Antibody-drug Conjugates for Tumors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2032) Figure 16. Global Antibody-drug Conjugates for Tumors Sales (2021-2032) & (K Units) Figure 17. Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Antibody-drug Conjugates for Tumors Sales YoY (2021-2032) & (K Units) Figure 20. Europe Antibody-drug Conjugates for Tumors Sales YoY (2021-2032) & (K Units) Figure 21. China Antibody-drug Conjugates for Tumors Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Antibody-drug Conjugates for Tumors Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Antibody-drug Conjugates for Tumors Sales YoY (2021-2032) & (K Units) Figure 24. Global Antibody-drug Conjugates for Tumors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Antibody-drug Conjugates for Tumors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Antibody-drug Conjugates for Tumors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2032) Figure 30. Global Antibody-drug Conjugates for Tumors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2032) Figure 33. Global Antibody-drug Conjugates for Tumors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2032) Figure 36. Global Antibody-drug Conjugates for Tumors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2032) Figure 39. North America Antibody-drug Conjugates for Tumors Revenue Share by Type (2021-2032) Figure 40. North America Antibody-drug Conjugates for Tumors Sales Share by Type (2021-2032) Figure 41. North America Antibody-drug Conjugates for Tumors Revenue Share by Application (2021-2032) Figure 42. North America Antibody-drug Conjugates for Tumors Sales Share by Application (2021-2032) Figure 43. North America Antibody-drug Conjugates for Tumors Revenue Share by Country (2021-2032) Figure 44. North America Antibody-drug Conjugates for Tumors Sales Share by Country (2021-2032) Figure 45. Europe Antibody-drug Conjugates for Tumors Revenue Share by Type (2021-2032) Figure 46. Europe Antibody-drug Conjugates for Tumors Sales Share by Type (2021-2032) Figure 47. Europe Antibody-drug Conjugates for Tumors Revenue Share by Application (2021-2032) Figure 48. Europe Antibody-drug Conjugates for Tumors Sales Share by Application (2021-2032) Figure 49. Europe Antibody-drug Conjugates for Tumors Revenue Share by Country (2021-2032) Figure 50. Europe Antibody-drug Conjugates for Tumors Sales Share by Country (2021-2032) Figure 51. China Antibody-drug Conjugates for Tumors Revenue Share by Type (2021-2032) Figure 52. China Antibody-drug Conjugates for Tumors Sales Share by Type (2021-2032) Figure 53. China Antibody-drug Conjugates for Tumors Revenue Share by Application (2021-2032) Figure 54. China Antibody-drug Conjugates for Tumors Sales Share by Application (2021-2032) Figure 55. Asia Antibody-drug Conjugates for Tumors Revenue Share by Type (2021-2032) Figure 56. Asia Antibody-drug Conjugates for Tumors Sales Share by Type (2021-2032) Figure 57. Asia Antibody-drug Conjugates for Tumors Revenue Share by Application (2021-2032) Figure 58. Asia Antibody-drug Conjugates for Tumors Sales Share by Application (2021-2032) Figure 59. Asia Antibody-drug Conjugates for Tumors Revenue Share by Country (2021-2032) Figure 60. Asia Antibody-drug Conjugates for Tumors Sales Share by Country (2021-2032) Figure 61. SAMEA Antibody-drug Conjugates for Tumors Revenue Share by Type (2021-2032) Figure 62. SAMEA Antibody-drug Conjugates for Tumors Sales Share by Type (2021-2032) Figure 63. SAMEA Antibody-drug Conjugates for Tumors Revenue Share by Application (2021-2032) Figure 64. SAMEA Antibody-drug Conjugates for Tumors Sales Share by Application (2021-2032) Figure 65. SAMEA Antibody-drug Conjugates for Tumors Revenue Share by Country (2021-2032) Figure 66. SAMEA Antibody-drug Conjugates for Tumors Sales Share by Country (2021-2032) Figure 67. Antibody-drug Conjugates for Tumors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Antibody-drug Conjugates for Tumors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • DNA Damaging Drugs
  • Tubulin Inhibitors
  • Other
Applications
  • Hematological Tumors
  • Solid Tumors
Companies covered
  • Takeda
  • RemeGen
  • Roche（Genentech）
  • Rakuten Medical
  • Gilead Sciences
  • Pfizer（Seagen)
  • GSK
  • Daiichi Sankyo
  • AbbVie(ImmunoGen)
  • AstraZeneca
  • ADC Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antibody-drug Conjugates for Tumors Market by Type
  3. 1.2.1 Global Antibody-drug Conjugates for Tumors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DNA Damaging Drugs
  5. 1.2.3 Tubulin Inhibitors
  6. 1.2.4 Other
  7. 1.3 Antibody-drug Conjugates for Tumors Market by Application
  8. 1.3.1 Global Antibody-drug Conjugates for Tumors Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hematological Tumors
  10. 1.3.3 Solid Tumors
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Antibody-drug Conjugates for Tumors Market Dynamics
  1. 2.1 Antibody-drug Conjugates for Tumors Industry Trends
  2. 2.2 Antibody-drug Conjugates for Tumors Industry Drivers
  3. 2.3 Antibody-drug Conjugates for Tumors Industry Opportunities and Challenges
  4. 2.4 Antibody-drug Conjugates for Tumors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antibody-drug Conjugates for Tumors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antibody-drug Conjugates for Tumors Revenue by Region
  3. 3.2.1 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antibody-drug Conjugates for Tumors Revenue by Region (2021-2026)
  5. 3.2.3 Global Antibody-drug Conjugates for Tumors Revenue by Region (2027-2032)
  6. 3.2.4 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antibody-drug Conjugates for Tumors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antibody-drug Conjugates for Tumors Sales by Region
  9. 3.4.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antibody-drug Conjugates for Tumors Sales by Region (2021-2026)
  11. 3.4.3 Global Antibody-drug Conjugates for Tumors Sales by Region (2027-2032)
  12. 3.4.4 Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antibody-drug Conjugates for Tumors Revenue by Manufacturers
  2. 4.1.1 Global Antibody-drug Conjugates for Tumors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antibody-drug Conjugates for Tumors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antibody-drug Conjugates for Tumors Sales by Manufacturers
  6. 4.2.1 Global Antibody-drug Conjugates for Tumors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antibody-drug Conjugates for Tumors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antibody-drug Conjugates for Tumors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antibody-drug Conjugates for Tumors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antibody-drug Conjugates for Tumors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antibody-drug Conjugates for Tumors Manufacturers, Product Type & Application
  13. 4.7 Global Antibody-drug Conjugates for Tumors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antibody-drug Conjugates for Tumors Market CR5 and HHI
  16. 4.8.2 2025 Antibody-drug Conjugates for Tumors Tier 1, Tier 2, and Tier 3
5 Antibody-drug Conjugates for Tumors Market by Type
  1. 5.1 Global Antibody-drug Conjugates for Tumors Revenue by Type
  2. 5.1.1 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antibody-drug Conjugates for Tumors Sales by Type
  6. 5.2.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antibody-drug Conjugates for Tumors Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antibody-drug Conjugates for Tumors Price by Type
6 Antibody-drug Conjugates for Tumors Market by Application
  1. 6.1 Global Antibody-drug Conjugates for Tumors Revenue by Application
  2. 6.1.1 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antibody-drug Conjugates for Tumors Sales by Application
  6. 6.2.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antibody-drug Conjugates for Tumors Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antibody-drug Conjugates for Tumors Price by Application
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Antibody-drug Conjugates for Tumors Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 RemeGen
  8. 7.2.1 RemeGen Company Information
  9. 7.2.2 RemeGen Business Overview
  10. 7.2.3 RemeGen Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 RemeGen Antibody-drug Conjugates for Tumors Product Portfolio
  12. 7.2.5 RemeGen Recent Developments
  13. 7.3 Roche（Genentech）
  14. 7.3.1 Roche（Genentech） Company Information
  15. 7.3.2 Roche（Genentech） Business Overview
  16. 7.3.3 Roche（Genentech） Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio
  18. 7.3.5 Roche（Genentech） Recent Developments
  19. 7.4 Rakuten Medical
  20. 7.4.1 Rakuten Medical Company Information
  21. 7.4.2 Rakuten Medical Business Overview
  22. 7.4.3 Rakuten Medical Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio
  24. 7.4.5 Rakuten Medical Recent Developments
  25. 7.5 Gilead Sciences
  26. 7.5.1 Gilead Sciences Company Information
  27. 7.5.2 Gilead Sciences Business Overview
  28. 7.5.3 Gilead Sciences Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio
  30. 7.5.5 Gilead Sciences Recent Developments
  31. 7.6 Pfizer（Seagen)
  32. 7.6.1 Pfizer（Seagen) Company Information
  33. 7.6.2 Pfizer（Seagen) Business Overview
  34. 7.6.3 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio
  36. 7.6.5 Pfizer（Seagen) Recent Developments
  37. 7.7 GSK
  38. 7.7.1 GSK Company Information
  39. 7.7.2 GSK Business Overview
  40. 7.7.3 GSK Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 GSK Antibody-drug Conjugates for Tumors Product Portfolio
  42. 7.7.5 GSK Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 AbbVie(ImmunoGen)
  50. 7.9.1 AbbVie(ImmunoGen) Company Information
  51. 7.9.2 AbbVie(ImmunoGen) Business Overview
  52. 7.9.3 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio
  54. 7.9.5 AbbVie(ImmunoGen) Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
  61. 7.11 ADC Therapeutics
  62. 7.11.1 ADC Therapeutics Company Information
  63. 7.11.2 ADC Therapeutics Business Overview
  64. 7.11.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio
  66. 7.11.5 ADC Therapeutics Recent Developments
8 North America
  1. 8.1 North America Antibody-drug Conjugates for Tumors Market Size by Type
  2. 8.1.1 North America Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
  3. 8.1.2 North America Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
  4. 8.1.3 North America Antibody-drug Conjugates for Tumors Price by Type (2021-2032)
  5. 8.2 North America Antibody-drug Conjugates for Tumors Market Size by Application
  6. 8.2.1 North America Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
  7. 8.2.2 North America Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
  8. 8.2.3 North America Antibody-drug Conjugates for Tumors Price by Application (2021-2032)
  9. 8.3 North America Antibody-drug Conjugates for Tumors Market Size by Country
  10. 8.3.1 North America Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antibody-drug Conjugates for Tumors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Antibody-drug Conjugates for Tumors Market Size by Type
  2. 9.1.1 Europe Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
  4. 9.1.3 Europe Antibody-drug Conjugates for Tumors Price by Type (2021-2032)
  5. 9.2 Europe Antibody-drug Conjugates for Tumors Market Size by Application
  6. 9.2.1 Europe Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
  8. 9.2.3 Europe Antibody-drug Conjugates for Tumors Price by Application (2021-2032)
  9. 9.3 Europe Antibody-drug Conjugates for Tumors Market Size by Country
  10. 9.3.1 Europe Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antibody-drug Conjugates for Tumors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Antibody-drug Conjugates for Tumors Market Size by Type
  2. 10.1.1 China Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
  3. 10.1.2 China Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
  4. 10.1.3 China Antibody-drug Conjugates for Tumors Price by Type (2021-2032)
  5. 10.2 China Antibody-drug Conjugates for Tumors Market Size by Application
  6. 10.2.1 China Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
  7. 10.2.2 China Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
  8. 10.2.3 China Antibody-drug Conjugates for Tumors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antibody-drug Conjugates for Tumors Market Size by Type
  2. 11.1.1 Asia Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
  4. 11.1.3 Asia Antibody-drug Conjugates for Tumors Price by Type (2021-2032)
  5. 11.2 Asia Antibody-drug Conjugates for Tumors Market Size by Application
  6. 11.2.1 Asia Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
  8. 11.2.3 Asia Antibody-drug Conjugates for Tumors Price by Application (2021-2032)
  9. 11.3 Asia Antibody-drug Conjugates for Tumors Market Size by Country
  10. 11.3.1 Asia Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antibody-drug Conjugates for Tumors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antibody-drug Conjugates for Tumors Market Size by Type
  2. 12.1.1 SAMEA Antibody-drug Conjugates for Tumors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antibody-drug Conjugates for Tumors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antibody-drug Conjugates for Tumors Price by Type (2021-2032)
  5. 12.2 SAMEA Antibody-drug Conjugates for Tumors Market Size by Application
  6. 12.2.1 SAMEA Antibody-drug Conjugates for Tumors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antibody-drug Conjugates for Tumors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antibody-drug Conjugates for Tumors Price by Application (2021-2032)
  9. 12.3 SAMEA Antibody-drug Conjugates for Tumors Market Size by Country
  10. 12.3.1 SAMEA Antibody-drug Conjugates for Tumors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antibody-drug Conjugates for Tumors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antibody-drug Conjugates for Tumors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antibody-drug Conjugates for Tumors Value Chain Analysis
  2. 13.1.1 Antibody-drug Conjugates for Tumors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antibody-drug Conjugates for Tumors Production Mode & Process
  6. 13.2 Antibody-drug Conjugates for Tumors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antibody-drug Conjugates for Tumors Distributors
  9. 13.2.3 Antibody-drug Conjugates for Tumors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst